HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock

This article was originally published in The Rose Sheet

Executive Summary

Janet Woodcock says FDA expected when the process was launched to complete all monographs by the year 2000, but 25 remain in tentative final monograph status, with a rulemaking required to finalize each one. “The rulemaking process … doesn’t work for getting monographs done in a very timely manner,” she says.

Advertisement

Related Content

All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
Transparency, Communication Needed In OTC Monograph System – PCPC
FDA Encourages Novel Switch Ideas, Though NSURE Remains Unsure
Advertisement
UsernamePublicRestriction

Register

RS018968

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel